Alumis Said Topline Results From Its Phase 3 ONWARD1 and ONWARD2 Trials of Envudeucitinib for Moderate-to-severe Plaque Psoriasis Met All Primary and Secondary Endpoints

Benzinga · 6d ago
  • Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis
  • Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average
  • Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program
  • Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 –